Pacylex
Edmonton
About Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers. The company is developing a small molecule, oral chemotherapeutic, PCLX-001, to exploit this cancer mechanism by turning on selective lethality, apoptosis, in these cancer cells. The company's approach exploits a previously-unknown therapeutic target in cancer, making the drug a first-in-kind therapy. The diagnostic technology identifies those patients who will benefit from the drug, sparing many patients needless treatment. Pacylex Pharmaceuticals was founded on 2012 and is headquartered in Edmonton, Alberta, Canada.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.2M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2022)
- Website: pacylex.com
- Phone: 1650-218-1840
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/pacylex-155597 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.